Incyte 胰腺癌药物联合化疗在 ESMO 公布持久肿瘤缓解结果
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte 在 ESMO 上表示，其靶向药物联合化疗在部分胰腺癌患者中诱导了持久的肿瘤缓解，这支持了公司此前将该疗法推进至后期临床试验的决定。该结果发布之际，Revolution Medicines 的胰腺癌药物 Rasonque 已于今年早些时候获批，显示针对 RAS 基因家族突变的药物可延长这类侵袭性癌症患者的生存。
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
MADRID — A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer — results, the biotech said, that support its prior decision to advance the treatment into a late-stage clinical trial.
The approval of Revolution Medicines’ pancreatic cancer drug Rasonque earlier this year showed that a medicine capable of attacking mutations in a group of genes called RAS could prolong survival for patients with the particularly aggressive cancer.
Now, companies like Incyte, Revolution Medicines, Verastem, and China’s Hengrui are developing next-generation drugs that selectively target specific mutations within the RAS family of genes, seeking even better results for patients.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com